Skip to Main Content

Key Action Statement Profile: KAS 6B

Aggregate evidence quality Grade B 
Benefits Reduced risk of influenza infection. Reduction in frequency of AOM associated with influenza. 
Risks, harms, cost Potential vaccine adverse effects. Cost of vaccine. Requires annual immunization. 
Benefits-harms assessment Preponderance of benefit. 
Value judgments Potential vaccine adverse effects are minimal. 
Intentional vagueness None 
Role of patient preferences Some parents may choose to refuse the vaccine. 
Exclusions See CDC guideline on contraindications (http://www.cdc.gov/flu/professionals/acip/shouldnot.htm). 
Strength Recommendation 
Aggregate evidence quality Grade B 
Benefits Reduced risk of influenza infection. Reduction in frequency of AOM associated with influenza. 
Risks, harms, cost Potential vaccine adverse effects. Cost of vaccine. Requires annual immunization. 
Benefits-harms assessment Preponderance of benefit. 
Value judgments Potential vaccine adverse effects are minimal. 
Intentional vagueness None 
Role of patient preferences Some parents may choose to refuse the vaccine. 
Exclusions See CDC guideline on contraindications (http://www.cdc.gov/flu/professionals/acip/shouldnot.htm). 
Strength Recommendation 
Close Modal

or Create an Account

Close Modal
Close Modal